Netherlands

Citi shifted NXP Semiconductors to a Neutral rating, citing weaker estimate revisions and limited data-center exposure relative to peers, a call that challenges the bullish narrative heading into the company's Q3 2026 earnings on October 27. The downgrade reframes the data-center gap that had been offset in the bull case by growing data-center control plane revenue projected to exceed US$500 million in 2026, even as automotive and industrial markets slow. NXP's narrative projects $17.6 billion in revenue and $4.7 billion in earnings by 2029, requiring 10.2% yearly revenue growth and roughly a $1.7 billion earnings increase from $3.0 billion today, with a $311.10 fair value implying 35% upside to the current price. The most bearish analysts already assumed only about 9.7% annual revenue growth and US$4.3 billion of earnings by 2029, and Citi's caution on limited AI data-center exposure may push that pessimistic scenario further. The development follows NXP's recent appearance at the Open Source Summit + Embedded Linux Conference Europe 2026 in Prague, where it highlighted its role in open-source and embedded Linux ecosystems.

According to data compiled by LSEG's IBES on the 8th, profits for companies in the STOXX Europe 600 index as a whole are expected to rise 21% year-on-year in the July-September quarter of 2026. While this is below the 23.9% increase in the April-June quarter of 2026, it is expected to be the second-highest quarterly profit growth rate in the past four years. Energy companies are showing high growth of about 2.2 times, but excluding them, growth comes to 9.7%, and real estate companies are expected to see a 71.5% decline in profit. Overall sales are also seen performing strongly, up 10.6%. Deutsche Bank noted in a report earlier this week that demand is solid and companies are able to pass on higher costs into prices, and that the impact of higher costs from elevated fuel prices is not as large as has been emphasized. Next week, Dutch semiconductor manufacturing equipment maker ASML Holding and Swedish telecommunications equipment giant Ericsson are among companies scheduled to report earnings.

The US government announced sanctions against the International Criminal Court, or ICC, just hours after Navanethem "Navi" Pillay, a former ICC judge, won the Nobel Peace Prize for her work in promoting peace and international law. Jørgen Watne Frydnes, chair of the Norwegian Nobel Committee, said Pillay played a key role in ensuring that war crimes, crimes against humanity and genocide are prosecuted under the law. The United States has previously imposed sanctions on ICC prosecutors and judges, but the measures announced today are far broader in scope, including penalties on private companies that provide services directly to the ICC. US Secretary of State Marco Rubio said in a statement that President Trump will never allow the International Criminal Court to prosecute Americans, and that the United States will bar transactions with this kangaroo court, cut off its resources and undermine its ability to operate. ICC Deputy Prosecutor Nazhat Shameem Khan condemned the sanctions, saying they are aimed at undermining the rule of law at the international level and will not be able to stop the court's work. The ICC currently has 125 member states, including all European Union members and all NATO members except the United States and Turkey, and is headquartered in The Hague in the Netherlands.

Six major banks published "Building Trust in Agentic Commerce" on September 22, 2026, a set of voluntary guardrails for agent-driven purchasing. The paper was authored by NatWest, Bank of America, ING, Capital One, Commonwealth Bank of Australia, and ASB Bank, and outlines five principles: transparency, safety, privacy and data protection, consumer choice, and interoperability. It is the first coordinated attempt by financial institutions to address how autonomous agents should behave when spending money on behalf of humans, though the framework establishes no compliance requirements, no enforcement mechanisms, and no penalties for non-adherence. The voluntary framing matters because the agentic commerce market is accelerating faster than regulatory frameworks can track, with Constructor's Stripe-powered Agentic Checkout and Meta and Sierra's Personal Agent Protocol both launching in October 2026. PYMNTS Intelligence reports that 93 percent of merchants believe AI and agent providers should bear the loss when agent-driven transactions go wrong, a liability question the six-bank framework does not address. Bank of America's head of digital payments described the guardrails as "a framework for responsible innovation," while NatWest's chief digital officer called them "a starting point for industry collaboration."

Russian prosecutors have filed an extradition request for senior officials of the International Criminal Court, or ICC, including ICC President Tomoko Akane, who is Japanese. Russia's Prosecutor General's Office sent the request to the Netherlands and other countries seeking the handover of nine ICC officials who were convicted in absentia by a Russian court last December. The dispute stems from 2023, when the ICC issued an arrest warrant for Russian President Vladimir Putin and other senior officials, alleging responsibility for the unlawful deportation and transfer of children from occupied areas of Ukraine to Russia. Japanese Deputy Chief Cabinet Secretary Masanao Ozaki said at a press conference in Tokyo that Russia's move is unjustifiable and unacceptable, adding that the Japanese government intends to respond appropriately, including by filing additional representations with Russia, and will maintain close communication with the ICC and other member states. The request comes as the ICC faces pressure from the United States, a Japanese ally, whose government under President Donald Trump announced sanctions on senior ICC leaders, including Akane, last August. Japanese Prime Minister Sanae Takaichi disclosed that she and President Trump exchanged candid views on the ICC during a meeting on the sidelines of the United Nations General Assembly last September.

A Dutch patent court has ruled in favor of Halozyme Therapeutics, finding that Merck's subcutaneous formulation of Keytruda infringes one of Halozyme's MDASE patents covering technology used to deliver drugs through subcutaneous injection. The ruling orders Merck to stop manufacturing and selling Keytruda SC in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands, and bars Merck from letting its affiliates continue selling the drug in those markets, including through its European marketing authorization. The order does not affect the intravenous version of Keytruda, which remains available to patients because it is not covered by Halozyme's patent or the injunction. It marks the second legal victory for Halozyme over Keytruda SC, following a December 2025 German preliminary injunction that stopped Merck from distributing or offering the drug in Germany, and Halozyme has also filed a separate U.S. patent infringement lawsuit alleging that Keytruda SC, marketed as Keytruda Qlex, infringes 15 of its MDASE patents. Merck said it strongly disagrees with the Dutch decision, considers Halozyme's patent invalid globally and the infringement allegation without merit, and is evaluating its next steps. The ruling is a setback for Merck as it seeks to expand Keytruda's use ahead of the loss of U.S. patent protection for the original formulation, with biosimilar competition potentially beginning in December 2028; the IV and SC versions together generate nearly half of Merck's topline. Halozyme said the MDASE technology in the Merck dispute is separate from its ENHANZE technology and licensing program, which is a major source of royalty revenue and has been used in 10 commercialized products across more than 100 markets, including Johnson & Johnson's Darzalex and argenx's Vyvgart. Halozyme shares have surged 65% year to date compared with the industry's 1% growth.

A Dutch court ruled in favor of Halozyme Therapeutics in late September 2026, issuing an injunction that halts manufacture and sale of Merck's subcutaneous Keytruda across eight European countries following a patent dispute. The decision affects one of Merck's key immuno-oncology formulations in important European markets, though it leaves the central near-term catalyst around late-stage oncology and cardiometabolic launches unchanged. Separately, Merck secured a new global license for SciBrunch's preclinical KRAS G12D inhibitor SPR2015, a deal carrying a US$400 million upfront charge that will weigh on reported earnings in the near term. Merck's narrative projects $75.3 billion in revenue and $22.5 billion in earnings by 2029, requiring 4.2% yearly revenue growth and a $19.3 billion earnings increase from $3.2 billion today, with a $155.68 fair value implying 10% upside. Some of the most optimistic analysts model roughly US$82.1 billion in revenue and US$30.2 billion in earnings by 2029, weighting pipeline breadth and AI-enabled efficiency more heavily than access risks such as the subcutaneous Keytruda ruling.

EQT has been drawn into the spotlight after Reuters reported the firm is among potential bidders for Dutch drone detection specialist Robin Radar Systems, in a possible deal valued near €2b. The report comes as EQT's share price has been under pressure, with the stock last closing at SEK279.5, a 1 month share price return down 10.45% and a year to date share price decline of 21.97%, even as the 3 year total shareholder return of 33.40% points to a stronger longer run journey than the past year's 18.02% total shareholder pullback suggests. The most widely followed narrative pegs fair value at about SEK386.9, implying the stock is 28% undervalued, while the current P/E of 27.8x sits far above both the Swedish Capital Markets industry on 16.9x and peers on 13.6x, and only slightly below a fair ratio of 28.1x. The EQT story could unravel if fundraising hits a ceiling or if tougher exit markets drag on carried interest and weaken the high-margin fee engine behind that valuation.

QIAGEN N.V. announced new artificial intelligence capabilities to help researchers analyze complex biological and genomic data faster while keeping the scientific evidence behind the results visible. The expansion includes IPA Investigator, a new AI research companion for QIAGEN Ingenuity Pathway Analysis, and the new QIAGEN Discovery Platform, which extends these capabilities into automated drug discovery workflows. The new offerings build on more than 25 years of biomedical knowledge from QIAGEN Digital Insights, whose bioinformatics solutions are used by around 150,000 users. The global market for AI in bioinformatics is projected to more than double from about $12 billion in 2026 to more than $25 billion by 2031, according to Mordor Intelligence. At the University of Bergen in Norway, researchers tested IPA Investigator using complex datasets that deliberately introduced misleading sample comparisons, and Dr. Simona Chera, Professor at the University of Bergen, said the tool identified the problem, cautioned against overinterpreting the results and suggested a better experimental design.

Nebius Group N.V. has acquired Inferize, an inference optimization company, to strengthen the production inference capabilities of its Nebius Token Factory managed inference platform, with the terms of the transaction not disclosed. The acquisition brings Inferize's technology and systems engineering team into Nebius Token Factory, and the technology is designed to reduce the time required to launch and scale large AI models and make inference workloads more elastic. Inferize's technology focuses on addressing cold starts, the time required for AI models to load before serving a request, which can leave assigned GPUs idle when demand rises and new instances are launched or when model weights are updated during workloads such as reinforcement learning. By reducing this idle GPU time, the technology is designed to let capacity scale more closely with actual usage while supporting higher capacity utilization and improved token economics. Management said Inferize brings technology aimed at accelerating how quickly systems respond to changing customer demand, along with a team experienced in GPU systems, and that the team's contribution is expected to extend beyond the initial integration. The deal adds another layer to Nebius' production inference efforts, following Eigen AI's model, kernel- and system-level optimization work and the addition of Clarifai's core team and licensed technology for system-level inference and compute orchestration.

ASML and Taiwan Semiconductor Manufacturing Co. are heading into earnings with investors focused less on recent results and more on how the market may respond. Both chipmakers have posted strong quarters yet saw their shares weaken afterward, and Awad expects the upcoming results to show whether semiconductor earnings can become catalysts again as expectations reset. ASML supplies lithography equipment while TSM operates as a major semiconductor foundry, giving the two a broader view of industry conditions because their businesses sit further up the chip supply chain. Investors may also scrutinize spending plans from large cloud companies for 2027 and whether AI costs are declining, with Awad pointing to lower pricing for some AI models and discounts from major providers as factors that could influence infrastructure spending. ASML is scheduled to report third-quarter results on Oct. 14, followed by TSM on Oct. 15, and Awad said the reactions could offer clues about how markets are assessing AI-related demand heading into 2027.

The Dutch government plans to levy a tax on investment gains, or Capital Gains Tax, starting in 2028, as part of a major overhaul of the country's wealth taxation system, shifting to taxing actual realised gains when assets are sold instead of the previous system based on assumed returns or unrealised gains. Prime Minister Rob Jetten and Finance Minister Elco Heinen said in a letter to the House of Representatives on Tuesday, September 29, that the cabinet chose the fastest feasible approach so that assets under the wealth tax system enter the capital gains tax regime as comprehensively as possible. On scope, the government proposes covering most financial instruments, including shares, bonds and options, aiming for roughly 90% of assets to enter the new tax system by 2028, while the remaining assets will be phased in over the following two years, or by 2030. At the same time, the government plans to set the tax-exempt threshold for income from savings and investments at 1,000 euros, or about 1,135 US dollars, starting in 2028, alongside improvements to other tax measures. However, the proposed legislative amendment still needs approval from the Dutch Senate by the end of 2026 before it can proceed on the scheduled timeline.

Juventus shares fell around 8.7% on Wednesday after the Italian football club reported a full-year net loss and announced plans for a capital increase of up to €250 million, or $283 million. The stock dropped to €1.58 during the session, its lowest price since June 2016. The Turin-based Serie A club said controlling shareholder Exor, the Agnelli family's holding company, would back the capital raise and immediately inject €60 million. This marks the fourth capital increase into the Serie A team since 2019, bringing the total to €1.15 billion. Juventus reported weaker than expected 2026 results, partly due to the acquisition of J|Hotel for €23 million, according to Kepler Chevreux, which put its rating under review and cut estimates to reflect a more cautious view about media contracts in 2026-27.